Remogliflozin etabonate-d 7

Overview

Remogliflozin etabonate-d 7 (GSK189075-d 7 ) is the deuterium labeled Remogliflozin etabonate. Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter ( SGLT2 ) inhibitor with K i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Others | Products > Signaling Pathways > Others | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Research Areas > Others | Products > Signaling Pathways > Isotope-Labeled Compounds | Products > Signaling Pathways > SGLT

Product Information

• Catalog No.: HY-166548S
• CAS No.: 1233515-93-9
• Molecular Formula: C26H31D7N2O9
• Molecular Weight: 529.63
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source